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Abstract
Background: Recent studies have shown an increasing incidence of herpes zoster (HZ) infection, which may be
related to the introduction of varicella vaccination programs in children. We examined the epidemiology and
treatment costs of HZ and post-herpetic neuralgia (PHN) over time in British Columbia, Canada.
Methods: The cohort consisted of all cases with HZ infection from January 1, 1997 and December 31, 2012.
Incident zoster was defined as a case (ICD-9 053 or ICD-10 B02) without a previous episode of HZ or PHN in the
previous 12 months. We determined the incidence for HZ and PHN and the age-sex standardized rate for the
overall population. We determined the association between the varicella vaccination program and increased HZ
rates by evaluating the rate ratios in the publicly-funded varicella vaccine period compared to the non-publicly
funded period in a regression model. We evaluated the hospitalization rates, treatment by GPs and their associated
yearly costs for HZ and PHN.
Results: HZ incidence increased for the entire study period from 3.2 per 1000 population in 1997 to 4.5 in 2012. HZ
rates were higher for females than males and all age groups had an increased incidence rate, except the 0–9 year
olds, where the rate decreased. Crude and age-sex standardized incidence rates of PHN demonstrated very similar
patterns to HZ incidence. Based on the regression model, rates of HZ were higher in the older individuals. No
significant increase with HZ incidence was seen during the publically funded varicella vaccination program
compared to the non-publicly funded period. From 1997 to 2012, the annual HZ-related costs associated with
hospitalizations and GP visits were over $CDN4.9 million and $CDN537,286, respectively; treatment costs for
hospitalizations have increased significantly over time. Majority of PHN-related cases are managed by GPs, with a
steady increase over time in number of cases and associated annual costs.
Conclusions: The incidence of zoster and PHN is increasing with time, particularly in the elderly population and
the risk is greater in the over 65 year olds. Treatment costs for both HZ and PHN represent a significant burden on
the Canadian healthcare system.
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Background
Varicella zoster virus (VZV) infection or chickenpox typic-
ally occurs in children and manifests as a diffuse itchy rash.
The rates of infection are high with approximately 95 % of
the population testing seropositive for VZV [1, 2]. Reactiva-
tion of the varicella virus later in life is known as herpes
zoster (HZ) infection [3], and is triggered when an individ-
ual’s immune system, cellular immunity in particular,
decreases due to the process of aging [4] or becomes im-
munocompromised [5]. Other risk factors for development
of HZ include race (Caucasians are at higher risk than
African Americans), gender (most studies show a higher in-
cidence among women), stress, trauma, and diabetes [6–8].
Herpes zoster infection manifests itself as a unilateral, ves-
icular, painful rash [9], and can lead to complications such
as post-herpetic neuralgia (PHN) [10, 11] in approximately
20 % of people.
Recent studies from Europe [12] and North America
[13] have shown a trend of increased zoster infection
rates over time. Scientists are unclear as to the reason
* Correspondence: fawziah@mail.ubc.ca
1University of British Columbia, Vancouver, BC, Canada
4University of British Columbia, 2405 Wesbrook Mall, Vancouver, British
Columbia V6T 1Z3, Canada
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Marra et al. BMC Infectious Diseases  (2016) 16:589 
DOI 10.1186/s12879-016-1898-z
for its increase, but Hope-Simpson in his original studies
had hypothesized that viral latency after infection with
VZV is maintained by “immunosurveillance”, which is
boosted by periodic subclinical reactivations and expos-
ure to exogenous virus [3, 14, 15]. Thus, HZ clinically
manifests itself when “immunosurveillance” falls below a
certain threshold [3]. Some have hypothesized that the
introduction of widespread childhood varicella vaccin-
ation programs could lead to less wild type virus boost-
ing for adults [16–18], leading to an increase in zoster
rates. Alternatively, the aging population and presence
of larger numbers of immunocompromised individuals
(due to autoimmune diseases, transplants and larger
numbers on medications such as corticosteroids,
DMARDS and biologics) [19] could also account for the
increase in zoster rates seen around the world [12, 13].
Given that it has been a decade since Canada evalu-
ated its rates of zoster infection [20, 21], we undertook
this study to determine the trends over time in age and
sex-specific herpes zoster and PHN rates. We further ex-
amined the rates of hospitalization and costs associated
with HZ and PHN over time. Finally, although not our
primary objective, we looked at the impact of varicella
vaccination on herpes zoster rates.
Methods
Data source
We used population-based data available from Population-
DataBC® which houses several health-related databases,
including the Medical Services Plan (MSP) [22] and
Discharge Abstract Database (DAD) [23]. These databases
use the International Classification of Diseases, Ninth
Revision (ICD-9) or Tenth Revision (ICD-10) to code for
medical billing. These two databases were linked to the out-
patient prescription database (PharmaNet) [24] and vital
statistics for cause of death (see Additional file 1: Table S1
for additional information on the data holdings). Individual
consent was not required for the records, however the
patient records/information was anonymized and de-
identified prior to analysis. Ethics approval for the study
was obtained from the University of British Columbia’s
Ethics Committee.
Study population
Individuals were eligible for inclusion in the cohort if they
were a resident of British Columbia between January 1,
1997 to December 31, 2012 with incident HZ. To improve
coding accuracy, we excluded visits or admissions with co-
existent codes for varicella (ICD-9 052 and ICD-10 B01).
An incident zoster case was defined as an enrollee with a
HZ ICD-9 (053) or ICD-10 (B02) code in the primary or
secondary position (i.e., all other) without any evidence of
HZ or PHN within 12 months prior to this incidence. All
25 diagnostic codes (primary as well as secondary codes)
in the hospitalization data were used to identify cases. If
the first position (or diagnosis) was the primary reason for
admission, all other positions from 2nd to 25th, if any,
were categorized as the secondary diagnostic codes. To
identify incident cases, we only included the first
outpatient visit or hospitalization during the study period
for each individual. In order to further ensure we were
obtaining incident zoster cases only, enrollees with only
PHN-specific ICD-9 (053.12, 053.13) or ICD-10 (B02.22,
B02.23) were excluded. We conducted a sensitivity ana-
lysis and used the methodology proposed by Zhang et al.
to increase positive predictive value of a HZ diagnosis in
an administrative data source by defining incident herpes
zoster as the presence of an ICD-9 or −10 code for herpes
zoster plus receipt of antivirals, acyclovir, valacyclovir,
famciclovir, within 7 days before or after the diagnostic
code for HZ [25].
PHN was identified as those individuals with a first epi-
sode of zoster with a further zoster diagnostic code after
90 days with a relevant prescription for analgesia, anticon-
vulsant, or antidepressant therapy on the same day as the
recorded consultation [26]. The presence of codes for non-
specific neuralgia or for neurological complications of
zoster after 90 days was also consistent with PHN.
Immunosuppression status was identified by the presence
of two diagnostic ICD-9 or ICD-10 codes on different days
as an outpatient or inpatient within one year prior to the
initial HZ diagnosis date. The following patients were
considered as immunosuppressed: hematopoietic stem cell
or solid organ transplantation; hematological malignancies
such as Hodgkin’s lymphoma, multiple myeloma, acute
leukemia, non-Hodgkin’s lymphoma; other hematological
diseases, such as aplastic anemia, agranulocytosis, myelo-
dysplastic syndrome; AIDS, advanced HIV infection; cancer,
and other disorders involving immunodeficiency (see
Additional file 1: Table S2 for ICD-9 and ICD-10 codes).
Statistical analysis
For our primary analysis, we calculated incidence as the
number of incident cases divided by the BC population.
The overall crude annual incidence rates (number of
events per 1000 population) of HZ and PHN was calcu-
lated by year and age group. We standardized the inci-
dence by age and sex using the 2006 Canadian census
data.
Varicella vaccines were introduced in Canada in 1998
but were implemented as part of routine immunization
programs in British Columbia in September 2004 and
January 2005 for susceptible kindergarten (age 6)/grade
6 students (age 12) and infants greater than or equal to
12 months of age, respectively [27]. At that time it was a
one-dose program, but was later changed to a two-dose
program January 1, 2012 [28]. The HZ vaccine, a live
attenuated vaccine containing the Oka/Merck strain of
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varicella-zoster virus, was marketed in 2008 in Canada
[29, 30]. We used a negative binomial regression model to
assess the impact of varicella vaccination on zoster inci-
dence during the three periods of the varicella vaccination
program: the pre-licensure period (1997–1998), the period
when the vaccine was available privately (1999–2004) and
the publicly funded one-dose vaccination period
(2005–2012). The model included age group, sex, im-
munosuppression status, indicator variables for varicella
vaccine implementation, and calendar year. Interaction
effects were assessed and sensitivity analysis was also
performed for those aged 65 years or older. To evaluate
risk factors for HZ, we calculated adjusted rate ratios for
age, sex, immunosuppression status and varicella vaccine
availability period using the regression model.
Finally, we evaluated the number and costs associated
with hospitalizations, General Practioner (GP) visits, and
treatment of HZ and PHN. Treatment for HZ was obtained
by linking the prescription database to the hospitalization
or GP office visit on that day and looking for antivirals,
analgesics, antidepressants, corticosteroids within 90 days
post-initial HZ visit. Each hospitalization inpatient record
was assigned at least one methodology-specific resource in-
tensity weight (RIW). The cost associated with acute care
hospitalization was estimated by multiplying the highest
RIW to the provincial estimates of the cost per weighted-
case (CPWC) (i.e., hospitalization cost = RIW*CPWC). The
cost associated with a GP visit was obtained from the
amount paid in the MSP billing system. Treatment cost
was defined as the total of drug cost submitted and the
pharmacy professional fee submitted (i.e., PharmaNet cost
= submitted drug cost + submitted professional fee). All
costs were inflated by multiplying the ratio of the British
Columbia consumer price index (CPI) for health care with
the base year of 2013.
All statistical tests were two-tailed and p = 0.05 used
to determine statistical significance. All analyses were
undertaken using SAS 9.4 (SAS Institute Inc., Cary, NC)
[31]. Bonferroni correction was applied in multiple




From 1997 to 2012, there were 238,295 incident cases of
herpes zoster in our study population, after excluding
201 cases with either co-existing varicella codes (n = 68)
or only PHN specific codes (n = 133) (Table 1). The
mean age of the zoster cases increased from 49.6 years
in 1997 to 53.2 years in 2012 and there were more
females than males (n = 138,855; 58.3 %). Among the
herpes zoster cases, 9526 (4.0 %) were immunosup-
pressed at the time of diagnosis; only 0.2 % (n = 516)
were vaccinated in our cohort.
Herpes zoster incidence
Crude HZ incidence increased with time from 2.9 per
1000 population in 1997 to 4.7 per 1000 population in
2012. As shown in Fig. 1, the age-sex standardized HZ
rates also illustrated the increasing trend between 1997
(3.2 per 1000 population) and 2012 (4.5 per 1000
population) (see Additional file 1: Table S3).
HZ incidence rates were strongly age-related (Fig. 2).
In 2012, the incidence in children and adolescents
(<20 years) was 1.3/1000 population (95 % CI: 1.2–1.4),
while in adults aged ≥50 years the incidence was 8.2/
1000 population (95 % CI: 8.1–8.4). This trend was
maintained each year during the whole study period.
Over time, zoster incidence increased in all age groups,
except 0–9 year age group which indicated a 50 %
decrease since 2004 from 1.6 to 0.8 per 1000 population
(Fig. 2). The highest increases in incidence from 1997 to
2012 were seen in age groups 40–49 years (2.4 to 3.9 per
1000 population, 63 % increase) and 60–69 years (5.4 to
8.7 per 1000 population, a 61 % increase). Although age
group 80 years and up had the highest incidence rate,
this age group experienced the lowest increase of 21 %
from 9.2 to 11.1 per 1000 population.
The incidence was significantly higher among females
compared to males across all the years (females: 3.35;
95%CI: 3.27, 3.43 vs males: 2.53; 95%CI: 2.46, 2.60 in
1997 and females: 5.48; 95%CI: 5.39, 5.58 vs males: 3.90;
95%CI: 3.82, 3.98 in 2012). This significant higher rate of
zoster infection in females persisted in almost all age
groups. There was a 19.3 % and 21.8 % increase in HZ
during the publicly funded varicella vaccine period
(3.869 per 1000 population) as compared to the privately
funded period (3.244 per 1000 population) and the
pre-licensure period (3.175 per 1000 population),
respectively (Table 2).
In order to increase specificity for the HZ case
definition, we conducted a sensitivity analysis of the case
definition, which was HZ accompanied with antiviral
taken within 7 days of diagnosis; the analysis of HZ
incidence showed a similar pattern to the primary
analysis (Fig. 1 and Additional file 1: Table S3).
PHN incidence
Crude and age-sex standardized incidence rate of PHN
demonstrated very similar patterns to the HZ incidence
(see Additional file 1: Table S2 for the crude analysis).
Figure 3 shows that the standardized rates increased al-
most 3-fold from 0.128 to 0.343 per 1000 population for
PHN defined within 90 days post HZ diagnosis. We saw
a similar result for our sensitivity analysis where PHN
was defined within 30 days post HZ diagnosis (age
adjusted rates increased from 0.104 to 0.296 per 1000
population (Fig. 3). All age groups showed increasing
incidence over the years (Fig. 4). The highest increase in
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PHN incidence within 90 days post initial HZ from 1997
to 2012 was found in age groups 40–49 years (5.6-fold
from 0.04 to 0.2 per 1000 population) and 10–19 years
(4.5-fold from 0.004 to 0.02 per 1000 population).
Although the age group of 80 years and up had the high-
est incidence rate, this age group experienced the lowest
increase (2.1-fold from 0.8 to 1.6 per 1000 population).
The incidence was significantly higher among females
compared to males across all the years (females: 0.14;
95%CI: 0.12, 0.15 vs males: 0.08; 95%CI: 0.07, 0.10 in
1997 and females: 0.42; 95%CI: 0.40, 0.45 vs males: 0.32;
95%CI: 0.30, 0.34 in 2012). Although females had higher
rates than males across all age groups, their differences
were not significant across the years. Similar patterns
were shown in our sensitivity analysis defined as PHN
within 30 days post HZ diagnosis.
Rate ratios comparisons on the impact of varicella
vaccine availability on HZ incidence
In our univariate analysis, the standardized mean annual
HZ incidence rates were significantly higher during the
publicly funded varicella vaccine period as compared to
privately funded period (rate ratio 1.193; 95 % CI: 1.180,
1.205) and pre-licensure period (rate ratio 1.218; 95 % CI:
1.199, 1.238) (Additional file 1: Table S4). However, in our
multivariate analysis, the risk of HZ during the publicly
funded varicella vaccine period was not statistically differ-
ent from the non-publicly funded period after controlling
for the effects of age, gender and immunosuppressive sta-
tus (Fig. 5, Additional file 1: Table S5). No significant
interaction effects were found. Age remained as having a
significant effect on the rate of HZ - the risk of HZ for
those 65 years of age and over was 2 times (1/0.5) higher
Table 1 Profile of Herpes Zoster Cases by Varicella Vaccine Availability, BC 1997–2012
Pre-licensure Privately Funded Publicly Funded Overall
1997–1998 1999–2004 2005–2012 1997–2012
Age
0–9 1577 (6.7 %) 4562 (5.9 %) 3619 (2.6 %) 9758 (4.1 %)
10–19 1422 (6 %) 4649 (6.1 %) 6995 (5.1 %) 13066 (5.5 %)
20–29 2073 (8.8 %) 6314 (8.2 %) 11706 (8.5 %) 20093 (8.4 %)
30–39 2952 (12.5 %) 8743 (11.4 %) 13304 (9.7 %) 24999 (10.5 %)
40–49 3098 (13.1 %) 10550 (13.7 %) 17872 (13 %) 31520 (13.2 %)
50–59 3332 (14.1 %) 12544 (16.3 %) 25707 (18.7 %) 41583 (17.5 %)
60–69 3397 (14.4 %) 11306 (14.7 %) 25270 (18.3 %) 39973 (16.8 %)
70–79 3682 (15.6 %) 11049 (14.4 %) 19552 (14.2 %) 34283 (14.4 %)
80+ 2089 (8.8 %) 7149 (9.3 %) 13738 (10 %) 22976 (9.6 %)
Unknown 12 (0.1 %) 24 (0 %) 8 (0 %) 44 (0 %)
Mean (IQR) 49.6 (33–69) 50.2 (34–69) 53.2 (39–69) 51.9 (36–69)
Gender
Male 10141 (42.9 %) 32247 (41.9 %) 56917 (41.3 %) 99305 (41.7 %)
Female 13453 (56.9 %) 44579 (58 %) 80823 (58.7 %) 138855 (58.3 %)
Unknown 40 (0.2 %) 64 (0.1 %) 31 (0 %) 135 (0.1 %)
Health Authority
Interior 4040 (17.1 %) 13659 (17.8 %) 24215 (17.6 %) 41914 (17.6 %)
Fraser 7470 (31.6 %) 24894 (32.4 %) 43316 (31.4 %) 75680 (31.8 %)
Vancouver Coastal 5684 (24.1 %) 17632 (22.9 %) 33518 (24.3 %) 56834 (23.9 %)
Island 4264 (18 %) 14231 (18.5 %) 26046 (18.9 %) 44541 (18.7 %)
Northern 1174 (5.0 %) 3667 (4.8 %) 7902 (5.7 %) 12743 (5.4 %)
Unknown 1002 (4.2 %) 2807 (3.7 %) 2774 (2 %) 6583 (2.8 %)
Immunosuppression Status (Any)
Yes 905 (3.8 %) 3121 (4.1 %) 5500 (4.0 %) 9526 (4.0 %)
No 22729 (96.2 %) 73769 (95.9 %) 132271 (96.0 %) 228769 (96.0 %)
Zoster Vaccinated
Yes NA NA 516 (0.4 %) 516 (0.2 %)
No 23634 (100 %) 76890 (100 %) 137255 (99.6 %) 237779 (99.8 %)
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than for those in age group 45–64 years, and 4.5 times (1/
0.22) higher than for those in age group 10–44 years. Al-
though females show a 16 % higher risk of HZ than males,
the effect was not statistical significant. We conducted a
similar analysis restricted to those aged 65 years and over
and the results were similar (data not shown).
Hospital admissions, GP visits and treatment related to
HZ and PHN
Table 3 shows that between 1997 and 2012, on a yearly
basis, 2 % of the initial cases were diagnosed through
hospitalization records, while the majority of HZ episodes
were non-hospitalized. The trend over time is a slight
decrease in the number of hospitalizations for treatment of
HZ, and a slight increase in the number of GP visits per
year with time. For those who were hospitalized the average
age was 73.0 years (SD: 18.3), with a median age of 78 years.
Majority of the patients were women (60.6 %), 2.7 % were
pediatric (i.e., 0–19 years), 14.3 % were adults (20–59 years)
and 82.9 % were 60 years and older. In contrast, the pa-
tients who visited their GPs, were younger - the average age
was 60.2 years (SD: 19.2), with a median age of 63 years.
Fifty eight percent were women, 3.9 % were pediatric (0–19
years), 38.7 % were adults (20–59 years) and 57.4 % were
60 years and older.
The annual cost of hospitalizing patients with HZ is
approximately $4.9 million, compared to $537,286 for
GP visits, resulting in an average cost per case of
$16,389 for hospitalization and $37 for GP-related visit.
Treatment was initiated in 53.4 % of the cases seen by
GPs and the majority of the cases (95 %) received antivi-
rals, thus when including costs associated with
Fig. 1 Crude and Age-Sex Standardized Herpes Zoster Incidence Rate and 95 % Confidence Interval by Year. The crude and age-sex adjusted rate
of herpes zoster and 95 % confidence interval between 1997 and 2012 using two different definitions of incident zoster: as defined by ICD9/10
code and as the presence of an ICD-9/10 code for herpes zoster plus receipt of antivirals within 7 days before or after the diagnostic code for HZ
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treatment, the annual cost per case of a GP-related visit
would increase by an additional $123 per case for initial
treatment of zoster infection. Subsequent visits to the
GP or hospitalization within 90 days of the initial HZ
diagnosis were very few. From 1997 to 2012, only 0.6 %
of cases were re-admitted into the hospital, with an
annual readmission cost of $12,149 per admission. In
contrast, on average, 26.4 % of cases re-visited their GP
within 90 days of their initial HZ diagnosis, costing an
additional $253,768 per year to the healthcare system.
Between 1997 to 2012, there were a total of 588
(0.2 %) cases with at least one hospitalization related to
PHN whereas the majority of the cases (total N= 14,054;
(5.9 %)) were seen by GPs. On a yearly average, there
were 39 hospitalizations and 1421 GP visits related to
PHN. The number of hospital admissions per year over
time has remained steady, but the annual number of GP
visits for treatment of PHN has increased with time. For
those who were hospitalized, the average age was
76.5 years (SD: 13.5), with a median age of 80 years and
62.9 % of the patients were women, 0.3 % were pediatric
(0–19 years), 9.7 % were adults (20–59 years) and 90.0 %
were 60 years and older. For patients who visited their
GPs, the average age was 66.7 years (SD: 14.8), with a
median age of 69 years and 60.4 % of the patients were
women, 0.6 % were pediatric (0–19 years), 27.5 % were
adults (20–59 years) and 71.9 % were 60 years and older.
Between 1997 and 2012, the total annual cost for
PHN-related hospitalization and GP visits were over
$552,740 and $12,709, respectively. Total costs per year
for PHN that is treated in by a GP have risen signifi-
cantly, from $5,693 to $19,048 per year. Prescription
costs associated with outpatient treatment of PHN were
estimated at $1.0 million (overall average $62,800/year)
and again have risen considerably over time, from
$17,011 to $91,544 per year. In contrast to HZ
treatment, medications used for PHN were primarily
anticonvulsants (61.7 %) and antidepressants (27.9 %).
Discussion
In our study, over the 16 year period, we saw a 1.5-fold
increase in HZ incidence regardless of the definitions
Table 2 Age-Sex Standardized Mean Annual Incidence Rate by Varicella Vaccine Availability Periods









































Fig. 2 Herpes Zoster Incidence Rate, by Age Group and Year. The rate of herpes zoster between 1997 and 2012, by various age groups
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used to identify herpes zoster. For young children
between the ages of 0 and 9 years, the HZ incidence
decreased abruptly from 1.8 to 0.8 per 1000 population
in 2004, and has been steadily declining, likely reflecting
the start of the publicly-funded varicella vaccination
program which targeted children in kindergarten (age
6 years). Interestingly, despite the introduction of the
varicella vaccination program in 2004 for 12 year olds,
the age-specific HZ incidence held steady but did not
decline for those within the 10–19 year old category.
This is probably related to the fact that most of them
will have had varicella infection already and have good
immunity; for now too little time has elapsed to show a
decrease in this age groups of HZ rates. Alternatively,
the lack of effect on HZ rates may be related to a lower
vaccine uptake rate in this age group than the kindergar-
teners or the fact that the vaccine effectiveness was
reduced with the one dose program. On the positive
side, zoster rates have not increased either, as they have
for all other age categories after the age of 19 years.
Although we saw a slight increase in zoster incidence in
the 20–39 year old age groups, the largest increases were
seen in the 40–49 (63 %) and the 60–69 year olds
(61 %). The 80 year old group had the highest incidence
Fig. 3 Age-Sex Standardized PHN Incidence Rate and 95 % Confidence Interval by Year. The age-sex adjusted rate of post-herpectic neuralgia between
1997 and 2012 using two different definitions of PHN: PHN diagnosed within 90 days post HZ diagnosis and within 30 days post HZ diagnosis
Fig. 4 Post-herpectic Neuralgia Incidence Rate, by Age Group and Year. The rate of post-herpectic neuralgia between 1997 and 2012, by various
age groups
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in 2012 (11/1000 population), although their increase
was only 21 % between 1997 and 2012. Our finding that
HZ incidence increases with age has been reported in
other studies and is thought to be related to immunose-
nescence, that is, decreasing ability to respond to the
reactivated virus as the body ages [4, 19]. Pinchinat and
colleagues [12] in their review of studies looking at the
incidence of HZ across Europe showed that HZ incidence
increases sharply with age, from around 1/1 000 children
<10 years up to 10/1 000 people over 80 years of age.
Similarly Kawai et al. found that age-specific incidence
was similar across countries and rose sharply after the age
of 50 years; their rates were similar to our study as they
found rates of 6-8/1000 person-years at age 60 years and
8-12/1000 person-years at age 80 years [13].
Our observation of a higher zoster incidence in women
has also been seen in other studies [7, 32–34]. Originally,
investigators believed this difference was not a real
phenomenon and it was likely due to women having
greater health-seeking behavior. However, given that the
difference between females and males occurs in all age
groups, including children, and has been seen consistently
in many studies using different methodologies, it is
unlikely that this phenomenon is due to differential
health-seeking behaviours. The biological reason behind
this effect is unclear; it may be related to symptomatic
zoster being more common in women, or gender
differences in immune responses to the varicella antigen
and loss of immunity over time [7, 35, 36].
In our study, the standardized rates seen in 2012 for
zoster were within the range reported in other North
American and European studies [12, 13]. In their system-
atic review Kawai et al. included 130 studies conducted in
26 countries. They found the incidence of HZ ranged
from 3 to 5 per 1000 person-years [13]. Although the
methodology used in these studies varied from prospective
surveillance to use of retrospective administrative data to
determine incidence, most of the studies showed a
temporal increase in the incidence of HZ and PHN in the
past several decades. The authors also observed that those
studies which evaluated all age groups (rather than
restricting the analyses to those over 60 years of age) and
were conducted in the 50s to early 90s, showed lower HZ
rates (HZ incidence of North American studies ranged
1.31 to 2.40 per 1000) [37, 38] than studies conducted
2000s (HZ incidence of North American studies ranged
3.82 to 5.79 per 1000) [35, 36, 39–41].
In our secondary analysis we evaluated the impact of
the introduction of the publicly funded varicella vaccin-
ation program. Between 2007 and 2012, the average cover-
age rates in the 2 year old, kindergarden (6 year old) and
grade 6 (12 year old) children was 83 %, 74 %, and 63 %,
respectively [42]. Despite these uptake rates, a vaccine ef-
fect was not seen after adjusting for potential confounders
which would have an effect on HZ incidence, including
age, sex, and immunosuppression status. Previous older
studies using survey data and modeling had suggested that
the introduction of a routine varicella vaccination
program could potentially increase the incidence of zoster
infections due to less boosting of immunity by the wild
type virus [16, 18, 19, 43, 44]. However, North American
studies conducted in the last 5 years, using large databases
have shown that although age-specific HZ incidence
is increasing, it started increasing before the introduction
of widespread varicella vaccination. Hales et al. [45]
conducted a retrospective study using Medicare claims to
examine the link between herpes zoster incidence in the
US population older than 65 years and childhood varicella
vaccination. They found that age and sex standardized HZ
incidence increased 39 % from 10.0 per 1000 person-years
Fig. 5 Rate Ratio on Herpes Zoster Incidence and 95 % Confidence Interval Using a Regression Model. The reference groups for the analyses
included publicly funded period, age 65+ years and male gender
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Table 3 Hospitalizations, General Practitioner Visits, and Treatment Costsa Associated with HZ and PHN
Pre-licensure Privately Funded Publicly Funded Overall
1997–1999 1999–2004 2005–2012 1997–2012
(3 years) (6 years) (8 years) (16 years)
Initial HZ Cases Identified Based on Hospitalization or GP Visits
Hospitalization (Annual count, %) 409 (3.5 %) 296 (2.3 %) 276 (1.6 %) 300 (2 %)
Annual Cost $4,747,242 $4,290,917 $5,428,559 $4,916,779
Cost/hospitalization Case $11,607 $14,505 $19,678 $16,389
GP Visit (Annual count, %) 11408 (96.5 %) 12519 (97.7 %) 16946 (98.4 %) 14593 (98 %)
Annual Cost $451,523 $475,046 $605,407 $537,286
Cost/GP Case $40 $38 $36 $37
Number of Cases Treated (Annual count, %)b 4889 (41.4 %) 6281 (49 %) 9987 (58 %) 7960 (53.4 %)
Annual Treatment Costs $750,370 $896,161 $1,091,457 $975,585
Cost/Rx Case $153 $143 $109 $123
Overall Annual Cost $5,949,134 $5,662,124 $7,125,422 $6,429,649
Overall Cost/Case $503 $442 $414 $432
HZ Related Hospitalization or GP Visits within 90 days Post Initial HZ Diagnosis
Hospitalization
Annual Casesc with ≥1 admission 109 (0.9 %) 84 (0.7 %) 93 (0.5 %) 91 (0.6 %)
Annual Cases with 0 admission 11708 (99.1 %) 12732 (99.3 %) 17129 (99.5 %) 14802 (99.4 %)
Annual Cost $1,164,402 $963,319 $1,381,308 $1,197,449
Cost/Admission $9,785 $10,763 $13,779 $12,149
GP Visits
Annual Casesc with ≥1 Visit 3207 (27.1 %) 3316 (25.9 %) 4588 (26.6 %) 3938 (26.4 %)
Annual Cases with 0 Visit 8610 (72.9 %) 9500 (74.1 %) 12634 (73.4 %) 10956 (73.6 %)
Annual Visits 8168 7602 12659 10201
Annual Visits with Rxd 1289 1458 2925 2170
Annual Visit Cost $219,145 $218,276 $289,042 $253,768
Annual Rx Cost $112,653 $122,106 $219,036 $169,389
Annual Cost (Visit + Rx) $331,798 $340,382 $508,078 $423,157
Cost/Visit (including Rx cost) $41 $45 $40 $41
PHN Related Hospitalization or GP Visits within 90 days Post Initial HZ Diagnosis
Hospitalization
Annual Casesc with ≥1 admission 39 (0.3 %) 35 (0.3 %) 37 (0.2 %) 37 (0.2 %)
Annual Cases with 0 admission 11778 (99.7 %) 12780 (99.7 %) 17184 (99.8 %) 14857 (99.8 %)
Annual Admission 43 38 40 39
Annual Cost $360,725 $539,429 $610,727 $552,740
Cost/Admission $8,488 $14,196 $15,364 $14,016
GP Visits
Annual Casesc with ≥1 Visit 416 (3.2 %) 614 (4.8 %) 1192 (6.9 %) 878 (5.9 %)
Annual Cases with 0 Visit 11410 (96.6 %) 12201 (95.2 %) 16029 (93.1 %) 14015 (94.1 %)
Annual Visits 606 901 2015 1421
Annual Visits with Rxe 478 751 1514 1098
Annual Visit Cost $5,693 $6,596 $19,048 $12,709
Annual Rx Cost $17,011 $39,874 $91,544 $62,851
Annual Cost (Visit + Rx) $22,704 $46,470 $110,592 $75,560
Cost/Visit $37 $52 $55 $53
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in 1992 to 13.9 per 1000 person-years in 2010. They used
Poisson regression analysis to compare HZ trends during
3 periods of varicella vaccination program implementa-
tion: preimplementation (1992 to 1995), early implemen-
tation (1996 to 1999), and full implementation (2000 to
2010). The authors also found that the rise in HZ inci-
dence predated 1996, when the U.S. Advisory Committee
on Immunization Practices first recommended routine
varicella vaccination for children aged 12 to 18 months,
and HZ incidence did not accelerate after full implemen-
tation of the varicella vaccination program, when vaccine
coverage reached 90 % and varicella incidence decreased
by 90 %. The authors of this paper also looked at HZ inci-
dence in US states that had low varicella vaccine coverage
rates compared to high coverage rates; they found that
state varicella vaccination coverage had no effect on HZ
incidence concurrently or 10 years later (RR, 0.9998 [CI,
0.9993 to 1.0003]) after adjusting their model for sex, age,
and calendar year [44]. Using medical claims data, Leung
and colleagues [38] evaluated HZ incidence in all persons
enrolled in the MarketScan® databases (Thomas Reuters,
Ann Arbor, MI). They used similar definitions as our
study and defined incident HZ as an enrollee of any age in
the MarketScan® database with an outpatient claim bear-
ing a HZ ICD-9 code (053.xx) in the primary or secondary
diagnostic position. From 1993 through 2006, HZ
incidence also increased 98 % from 1.7 (95%CI: 1.6-1.7) in
1993 to 4.4 (95 % CI: 4.3-4.4) in 2006. The increases
occurred among all age strata and both sexes, although it
increased more rapidly among females. Their results
suggested greater increase in HZ rates between 1993 and
1996, prior to introduction of the varicella vaccination
program. They also did not find any variation in HZ
incidence by state varicella vaccination coverage rates. An
interesting observation by the authors was that adults with
dependents less than 12 years of age had lower HZ inci-
dence at the outset of the varicella vaccination program
compared with adults without dependents. However, the
incidence in both groups became similar as the program
progressed, suggesting that the introduction of the
varicella vaccination program has not influenced HZ inci-
dence in the general population, but it may have affected
specific groups or households. In a recent Canadian epide-
miologic study, Russell et al. [40] used multiple linked
datasets to determine the incidence of HZ in Alberta,
Canada and the impact of the varicella vaccination pro-
gram, which has been publicly funded since 2002. Similar
to our study, they showed that crude rates of medically
attended HZ episodes increased over the interval of
1994–2010. Herpes zoster rate was 3.5 per 1000 person-
years in 1994, 3.8/1000 person-years in 1998, 4.0/1000
person-years in 2001 and 4.5/1000 person-years by 2010.
Rates were higher among females than males over the
entire interval, and increased more rapidly for females
than males. As in our study, prior to the publicly-funded
varicella vaccination program in 2002, all age groups expe-
rienced increasing annual rates of HZ, but a sharp decline
was seen in those less than 10 years of age for 2002–2010,
the period in which varicella vaccination was publicly
funded by the government. Other recent studies con-
ducted in Australia [46], Japan [47] and Taiwan [48, 49]
also have found that zoster rates were increasing before
the introduction of their varicella vaccination programs.
Although our study findings is in agreement with these
studies, our data should be interpreted with caution. The
varicella impact model we used may not capture the influ-
ence on zoster of varicella vaccination, because time pe-
riods we used were based on time of varicella vaccination
policy changes and we did not allow for the impact of that
vaccination on chickenpox rates to be seen. Because we
did not allow for a lag time to see reductions in childhood
varicella rates after introduction of a new vaccination pro-
gram, we may have missed the true impact of childhood
varicella vaccination program on HZ rates.
In our study we saw a very low PHN incidence of
0.343 per 1000 persons compared to the SPS trial [29],
which showed the PHN incidence to be 1.38 per 1000 in
the placebo group. In the systematic review conducted
by Kawai et al., the risk of developing PHN ranged
widely from 5 % to 30 % because of the different defini-
tions used by researchers to classify duration, severity of
pain and also because of differing comorbid illnesses,
age and other underlying risk factors from one study to
another [13]. The low incidence of PHN seen in our
study is comparable to other studies using administrative
databases to estimate PHN incidence; these studies are
more likely to report a lower estimated risk of PHN
compared with prospective studies (2.6 % to 6.9 %)
[50–53]. This is likely the result of misclassification bias
when using billing codes rather than actual medical re-
cords to delineate PHN. Further, the definition of PHN
varies widely from one study to another and therefore,
the incidence varies depending on whether the study
uses the 90 day or 30 definition, making the direct
aAll Costs were adjusted to 2013 British Columbia Consumer Price Index, Health and Personal Care
bPrescriptions on the same day of GP visits related to initial HZ treatment were antivirals (94.5 %), anticonvulsants (5.5 %), antidepressants (3.9 %), corticosteroids
(2.6 %), NSAIDS (2.5 %), immunosuppressants (0.1 %), non-NSAID analgesia (0.0 %)
cCase refers to the number of patients with at least one related PHN or HZ hospital admission or GP visits 90 days after initial HZ diagnosis
dPrescriptions on the same day of GP visits related to HZ treatment were anticonvulsants (40.3 %), antivirals (38.6 %), antidepressants (18.3 %), NSAIDS (6.8 %),
corticosteroids (6.5 %), immunosuppressants (0.2 %), non-NSAID analgesia (0.1 %)
ePrescription on the same day of GP visits related to PHN were anticonvulsants (61.7 %), antidepressants (27.9 %), NSAIDS (9.8 %), corticosteroids (8.7 %), antivirals
(7.5 %), non-NSAID analgesia (0.2 %), immunosuppressant (0.2 %)
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comparison difficult across studies. Regardless of the
definition, we did see a significant increase in the
incidence of PHN between 1997 and 2012. Given that
the definition of PHN included a diagnosis of zoster, we
had expected to see a rise in PHN incidence but the
magnitude of a 3-fold increase was a surprise. Although
some of this increase is likely real and the result of the
increase in HZ rates, we feel it may also be related to
increasing recognition and awareness by the public and
medical community about PHN being a common com-
plication of zoster. Like previous studies, we also showed
that the highest incidence of PHN was in the older indi-
viduals, especially those over the ages of 70 years, but in
terms of increasing incidence with time, we saw the
largest increase in those 40–49 years and 10–19 years.
Understanding of the risk factors for PHN has evolved
over the years; not only are older age, greater pain and
rash severity, and presence of a prodrome known to be
risk factors for PHN, but newer evidence would suggest
immunosuppression, diabetes and trauma to also be risk
factors for PHN [4, 54]. It may be that the younger
cohort are more immunosuppressed due to specific
diseases or medications, or the proportion of young
adults with diabetes is increasing, or perhaps they or
their parents are more prone to seeking medical
attention for PHN symptoms than the elderly.
Between 1997 and 2012, only 0.6 % (6 per 1000 popu-
lation) of our HZ cases were hospitalized, and over time
we saw a slight decrease in the hospitalization rate from
0.9 % in 1997 to 0.5 % in 2012. Studies that have re-
ported on hospitalization rates for HZ show a wide vari-
ation with reported rates ranging from 2 to 25/100 000
person-years in studies examining all ages [13]; the vari-
ation is probably related to differing admission criteria
and whether studies used the HZ primary code or all
codes for diagnosis. In our study, we saw that the mean
age of patients hospitalized was higher and in the
mid-seventies compared to those being seen by their
GPs. Although we did not breakdown our data by age,
studies have shown that hospitalization rates increase
with age. For example, Jackson et al. reported
hospitalization rates of 10 per 100,000 in adults 60–69
years of age but 65 per 100,000 in adults 80 years old or
above [55]. Rates of hospitalization, in an Australian
study, showed similar increases from 13 per 100,000 to
96 per 100,000 in adults 60–64 years of age and those
≥80 years of age respectively [56].
In our dataset, despite seeing a slight decrease in the
number of hospitalizations for the treatment of HZ, we
saw a significant increase in hospitalization costs over
time. We believe, this may be related to more compli-
cated cases being admitted for treatment while uncom-
plicated cases are being treated as outpatients, as we
also saw an increase in the number of cases seen per
year by GPs with HZ. Ninety-five percent of our HZ
patients were treated with antivirals, which is similar to
rates seen in studies conducted in Germany (71 %) [57],
Italy (79 %) [51], and France (94 %) [58]. In general per
case treatment costs of inpatients with HZ are approxi-
mately $16,000 and outpatients is around $40 per GP
visit (an additional $123 if you include medications).
With respect to PHN, we saw that most PHN cases were
being treated on an outpatient basis, again with an
increase over time with respect to the number of cases
being seen by GPs. Like HZ, we saw an increase in the
treatment costs associated with PHN. Costs associated
for PHN treatment in the hospital is approximately
$14,000 per case and for outpatients is $53 per visit.
Given the numbers of patients who have a diagnosis of
PHN, the annual cost of visiting a GP and receiving
treatment is $75,560 to the healthcare system. It is
difficult to compare cost data to other studies as the ap-
proaches used to calculate costs are so different; some
studies look at direct and indirect costs while others, like
ours look at direct costs only; some look at outpatient
visits only, while other studies look at all medical
expenses. Gauthier et al. estimated the mean total cost
in their study of inpatient to be £103 ($206) per HZ case
and £397 ($794) per HZ case for outpatient care [36].
This is in contrast to our study which showed higher
hospitalization costs rather than outpatient costs. In an
Italian study, the mean inpatient treatment costs for HZ
was €2592 ($4147) while outpatient costs were €123
($197) [51]. While the trends are similar to our study –
higher costs for hospital visits – our costs were much
higher for HZ hospitalization ($16,389) but similar for
outpatient costs ($160).
Although our data with respect to the increase in HZ
and PHN rates over time agree with previously reported
studies, this may be an artifact given that ours is an epi-
demiological study using large datasets, and we were not
able to directly access the accuracy of the administrative
database claims through record reviews. As with all
studies using administrative data, we used billing codes
meant for physician billing as our basis to delineate
zoster and PHN diagnosis. Because of this, changes in
coding or coding errors could have led to an over- or
under-estimation of the results. To try and overcome
some of these issues and increase specificity, we used
alternative definitions and found similar results to our
main analysis. Our study was limited by the data
available in the databases so if patients did not approach
a medical facility for their zoster infection or PHN treat-
ment, we would not have captured these events or their
costs in our analyses, thereby underestimating their inci-
dence; this may be particularly true around PHN-related
costs as patients could have had alternative treatments
for pain control. It is also possible that increasing HZ
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and PHN rates are simply due to improved coding and
awareness. This may be especially true after the herpes
zoster vaccine was marketed in 2008 as both the public
and the medical community have been better educated
on signs and symptoms of herpes zoster, the use of anti-
virals and analgesics for its treatment and complications
arising from zoster infection, particularly PHN. Around
the time the zoster vaccine was marketed in Canada,
pharmacists received the authority to immunize and one
of the vaccines they are heavily promoting to their
clients is the herpes zoster vaccine, further enhancing
awareness of the disease. However having said that, we
know that between 2008 and 2012, the herpes zoster
vaccine was marketed as a freezer-stable product and
the uptake rate of the vaccine was less than 10 %.
Although we adjusted for age and sex, we are not able to
control for all the potential confounders which may have
affected the HZ and PHN rates. In particular, the pro-
portion of the population which has comorbidities such
as diabetes mellitus (a known risk factor for HZ), and
immunocompromising conditions such as solid organ
transplants, cancer, leukemia/lymphoma, or being on
medications that decrease T-cells (TNF-alpha inhibitors,
DMARDS, corticosteroids) has increased over time,
leading to increased numbers of patients being at risk
for HZ/PHN [59]. Finally, as with all epidemiological
studies, there may be additional risk factors for zoster
and PHN that we are unaware of at the present time
and these would not have been adjusted for in our study.
Conclusions
In conclusion, we found the incidence of zoster and
PHN is increasing with time. Although there are well
known risk factors, such as age, female gender and being
immunocompromised, which are contributing to the in-
creased incidence seen with time, there are obviously
risk factors present which are more difficult to tease out,
such as trauma, psychological stress, race, and family
history. Understanding the epidemiology and risk factors
of HZ is critical for better targeting of treatment and
prevention strategies.
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